Document Detail


Multiple roles of protein kinase a in arachidonic acid-mediated Ca2+ entry and tumor-derived human endothelial cell migration.
MedLine Citation:
PMID:  20870737     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
We recently showed that arachidonic acid (AA) triggers calcium signals in endothelial cells derived from human breast carcinoma (B-TEC). In particular, AA-dependent Ca(2+) entry is involved in the early steps of tumor angiogenesis in vitro. Here, we investigated the multiple roles of the nitric oxide (NO) and cyclic AMP/protein kinase A (PKA) pathways in AA-mediated Ca(2+) signaling in the same cells. B-TEC stimulation with 5 μmol/L AA resulted in endothelial NO synthase (NOS) phosphorylation at Ser(1177), and NO release was measured with the fluorescent NO-sensitive probe DAR4M-AM. PKA inhibition by the use of the membrane-permeable PKA inhibitory peptide myristoylated PKI(14-22) completely prevented both AA- and NO-induced calcium entry and abolished B-TEC migration promoted by AA. AA-dependent calcium entry and cell migration were significantly affected by both the NOS inhibitor N(G)-nitro-l-arginine methyl ester and the NO scavenger 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl 3-oxide, suggesting that NO release is functionally involved in the signaling dependent on AA. Moreover, pretreatment with carboxyamidotriazole, an antiangiogenic compound that interferes with agonist-activated calcium entry, prevented AA-dependent B-TEC motility. Interestingly, even in the absence of AA, enhancement of the cyclic AMP/PKA pathway with the adenylyl cyclase activator forskolin evoked a calcium entry dependent on NOS recruitment and NO release. The functional relevance of AA-induced calcium entry could be restricted to tumor-derived endothelial cells (EC) because AA evoked a smaller calcium entry in normal human microvascular ECs compared with B-TECs, and even more importantly, it was unable to promote cell motility in wound healing assay. This evidence opens an intriguing opportunity for differential pharmacologic treatment between normal and tumor-derived human ECs.
Authors:
Alessandra Fiorio Pla; Tullio Genova; Emanuela Pupo; Cristiana Tomatis; Armando Genazzani; Roberta Zaninetti; Luca Munaron
Related Documents :
15107407 - Lipoxygenase-dependent superoxide release in skeletal muscle.
9886417 - Characterization of the signal transduction pathway activated in human monocytes and de...
11181087 - Arachidonyltrifluoromethy ketone, a phospholipase a(2) antagonist, induces dispersal of...
9678777 - Influence of cellular incorporation of n-3 eicosapentaenoic acid on intracellular ca2+ ...
3982587 - Release of preloaded taurine and hypotaurine from astrocytes in primary culture: stimul...
10096777 - Ucl 1684: a potent blocker of ca2+ -activated k+ channels in rat adrenal chromaffin cel...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-09-24
Journal Detail:
Title:  Molecular cancer research : MCR     Volume:  8     ISSN:  1557-3125     ISO Abbreviation:  Mol. Cancer Res.     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-11-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101150042     Medline TA:  Mol Cancer Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1466-76     Citation Subset:  IM    
Copyright Information:
©2010 AACR.
Affiliation:
Department of Animal and Human Biology, University of Turin, Via Accademia Albertina 13, 10123 Turin, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cancer and the complement cascade.
Next Document:  DNA damage-induced modulation of GLUT3 expression is mediated through p53-independent extracellular ...